Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma
Therapeutic options for metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum‐based chemotherapy are limited. Topotecan is an approved second‐line chemotherapy for small cell lung cancer (SCLC). NEC is often considered to show a biological behavior similar to SCLC. The...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 May 2016
|
| In: |
Cancer medicine
Year: 2016, Jahrgang: 5, Heft: 9, Pages: 2261-2267 |
| ISSN: | 2045-7634 |
| DOI: | 10.1002/cam4.807 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1002/cam4.807 Verlag, kostenfrei, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055186/ 
|
| Verfasserangaben: | Leonidas Apostolidis, Frank Bergmann, Dirk Jäger, Eva Caroline Winkler |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1566987415 | ||
| 003 | DE-627 | ||
| 005 | 20240316100314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180109s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.807 |2 doi | |
| 035 | |a (DE-627)1566987415 | ||
| 035 | |a (DE-576)496987410 | ||
| 035 | |a (DE-599)BSZ496987410 | ||
| 035 | |a (OCoLC)1340985775 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Apostolidis, Leonidas |d 1981- |e VerfasserIn |0 (DE-588)139136932 |0 (DE-627)703220594 |0 (DE-576)309798590 |4 aut | |
| 245 | 1 | 0 | |a Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma |c Leonidas Apostolidis, Frank Bergmann, Dirk Jäger, Eva Caroline Winkler |
| 264 | 1 | |c 29 May 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.01.2018 | ||
| 520 | |a Therapeutic options for metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum‐based chemotherapy are limited. Topotecan is an approved second‐line chemotherapy for small cell lung cancer (SCLC). NEC is often considered to show a biological behavior similar to SCLC. The aim of this study was to analyze the efficacy of topotecan in pretreated metastatic NEC patients. We performed a retrospective analysis of all patients treated with topotecan for metastatic NEC who presented at our center between January 2005 and December 2014 (n = 30). All 30 patients had received at least a platinum and etoposide containing regimen as prior chemotherapy. Median proliferation rate (Ki67) was 80%. As best response to topotecan five patients showed a stable disease, two patients a partial remission, resulting in a disease control rate of 23%. Of the remaining 23 patients, 14 (47%) showed a progressive disease, nine (30%) died before radiologic response could be evaluated. Median progression‐free (PFS) and overall survival (OS) after start of topotecan was 2.1 and 4.1 months, respectively. In the subgroup analysis, patients with unknown primary (vs. those with a known primary) showed a significantly prolonged PFS of 3.5 months (vs. 1.9, P = 0.0107) and OS of 6.7 months (vs. 2.6 months, P = 0.0168). Grade 3/4 hematotoxicity was observed in 60% of patients. Topotecan shows only moderate antitumor activity in metastatic NEC. Disease control rate is lower than reported for SCLC. However, antitumor activity of topotecan seems higher in patients with unknown primary. | ||
| 700 | 1 | |a Bergmann, Frank |d 1972- |e VerfasserIn |0 (DE-588)124407900 |0 (DE-627)363326081 |0 (DE-576)294157840 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Winkler, Eva C. |d 1971- |e VerfasserIn |0 (DE-588)1055853065 |0 (DE-627)792734823 |0 (DE-576)411905384 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d Hoboken, NJ : Wiley, 2012 |g 5(2016), 9, Seite 2261-2267 |h Online-Ressource |w (DE-627)71860153X |w (DE-600)2659751-2 |w (DE-576)366682164 |x 2045-7634 |7 nnas |a Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma |
| 773 | 1 | 8 | |g volume:5 |g year:2016 |g number:9 |g pages:2261-2267 |g extent:7 |a Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.807 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055186/ |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20180109 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1055853065 |a Winkler, Eva C. |m 1055853065:Winkler, Eva C. |d 910000 |d 912900 |d 50000 |e 910000PW1055853065 |e 912900PW1055853065 |e 50000PW1055853065 |k 0/910000/ |k 1/910000/912900/ |k 0/50000/ |p 4 |y j | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 3 | ||
| 998 | |g 124407900 |a Bergmann, Frank |m 124407900:Bergmann, Frank |d 910000 |d 912000 |d 50000 |e 910000PB124407900 |e 912000PB124407900 |e 50000PB124407900 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 2 | ||
| 998 | |g 139136932 |a Apostolidis, Leonidas |m 139136932:Apostolidis, Leonidas |d 910000 |e 910000PA139136932 |k 0/910000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1566987415 |e 2992278629 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"7 S."}],"id":{"doi":["10.1002/cam4.807"],"eki":["1566987415"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 09.01.2018"],"relHost":[{"language":["eng"],"disp":"Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinomaCancer medicine","recId":"71860153X","pubHistory":["1.2012 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Cancer medicine","title_sort":"Cancer medicine"}],"origin":[{"publisher":"Wiley","dateIssuedDisp":"2012-","dateIssuedKey":"2012","publisherPlace":"Hoboken, NJ"}],"note":["Gesehen am 07.05.13"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2045-7634"],"zdb":["2659751-2"],"eki":["71860153X"]},"part":{"text":"5(2016), 9, Seite 2261-2267","volume":"5","pages":"2261-2267","year":"2016","issue":"9","extent":"7"}}],"person":[{"family":"Apostolidis","given":"Leonidas","display":"Apostolidis, Leonidas","role":"aut"},{"role":"aut","display":"Bergmann, Frank","given":"Frank","family":"Bergmann"},{"given":"Dirk","display":"Jäger, Dirk","family":"Jäger","role":"aut"},{"family":"Winkler","given":"Eva C.","display":"Winkler, Eva C.","role":"aut"}],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"29 May 2016"}],"name":{"displayForm":["Leonidas Apostolidis, Frank Bergmann, Dirk Jäger, Eva Caroline Winkler"]},"recId":"1566987415","title":[{"title_sort":"Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma","title":"Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma"}],"language":["eng"]} | ||
| SRT | |a APOSTOLIDIEFFICACYOF2920 | ||